bioAffinity Technologies, Inc. (BIAF) Stock Ticker
BIAF right now
Market factors today
Unlock the full BIAF picture
About bioAffinity Technologies, Inc.
As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.
BIAF stock facts
| Ticker symbol | BIAF |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Medical - Diagnostics & Research |
| Market cap | $3.3M |
| CEO | Maria Zannes |
| Employees | 57 |
| Headquarters | San Antonio, TX, US |
| IPO date | 2022-09-01 |
| Website | www.bioaffinitytech.com |
What you can see for BIAF on Tickr
Live BIAF price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the BIAF report.
Rankings
FAQ
What is the ticker symbol for bioAffinity Technologies, Inc.?
The ticker symbol for bioAffinity Technologies, Inc. is BIAF, listed on the NASDAQ Capital Market.
What is BIAF?
As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular…